Sign In
Buy ITRM
$0.0300
+0 (+0%)
At Close: Jun 03, 2026
Iterum Therapeutics News: Why ITRM Stock Is Rocketing Higher Today
10:54am, Thursday, 03'rd Dec 2020
Iterum Therapeutics (ITRM) is in the news Thursday following news of massive stakes in the company pushing ITRM stock higher. The post Iterum Therapeutics News: Why ITRM Stock Is Rocketing Higher Toda
Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
09:15am, Monday, 30'th Nov 2020
-- F irst O ral Penem in the U . S . and First New Oral Treatment for uUTI s in Over 20 Years , if approved - - - - Potential Approval Q3 2021 with Priority Review --
Iterum Therapeutics Reports Third Quarter 2020 Financial Results
06:45am, Monday, 16'th Nov 2020
NDA Filing Expected Q4 2020 NDA Filing Expected Q4 2020
Iterum Therapeutics Commences Rights Offering
12:00pm, Tuesday, 11'th Aug 2020
DUBLIN, Ireland and CHICAGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation
Iterum Therapeutics Reports Second Quarter 2020 Financial Results
10:45am, Thursday, 06'th Aug 2020
\--Meeting with FDA Scheduled for end of Q3--DUBLIN, Ireland and CHICAGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on d
Iterum Therapeutics Informs Shareholders of Record Date for Planned Rights Offering
08:05pm, Monday, 13'th Jul 2020
DUBLIN, Ireland and CHICAGO, July 13, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation
Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
01:12pm, Tuesday, 30'th Jun 2020
Iterum Therapeutics plc (ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community
Iterum Therapeutics plc (ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community
Iterum Therapeutics plc Announces Result of Proposal 8 at Annual General Meeting
08:30pm, Monday, 15'th Jun 2020
Resolution No. 8 sought approval for the acquisition by investment funds managed and controlled by Sarissa Capital Management LP (together the Sarissa Funds) of up to 60% of the total issued ordinary
What’s Next for Iterum (ITRM) After Sulopenem Fails Phase 3 Trial? Top Analyst Weighs In
07:45pm, Wednesday, 03'rd Jun 2020
Should biotechs come with a volatility warning label attached? Most followers of the sector probably already know the risks involved when investing in a biotech stock; The possibility of mercurial gai
Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
01:50pm, Wednesday, 03'rd Jun 2020
Iterum Therapeutics plc (ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in bo
Company News for June 2, 2020
01:42pm, Tuesday, 02'nd Jun 2020
Companies in the news are: MYOV, ITRM, COTY, OPK
Iterum Therapeutics plc (ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in bo
3 Biotech Stocks Under $4 That Could Surge Over 50%
01:31pm, Thursday, 14'th May 2020
It has been almost three months since the coronavirus-driven volatility hit the global economy, and the market continues to rapidly move into both the green and the red. Yet, since its March 16 low, t
Iterum Therapeutics Reports First Quarter 2020 Financial Results
10:45am, Thursday, 14'th May 2020
--Phase 3 topline results from sulopenem clinical trials in uUTI and cUTI expected Q2 -- -- Raised $51.6 million through a private placement with new and existing.
